Nanoemulsion therapeutic compositions and methods of using the same

Patent metadata

Field	Value
Publication number	US-9259407-B2
Application number	US-201514628886-A
Country	US
Kind code	B2
Filing date	Feb 23, 2015
Priority date	Sep 26, 2008
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia ) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

First claim

We claim:

1. A method of treating an infection of a wound comprising administering a composition comprising a therapeutically effective amount of a nanoemulsion, wherein the nanoemulsion comprises:
1. 30-90%, 60-80%, or 60-70% by volume oil;
2. 3-15% by volume solvent; wherein said solvent is selected from the group consisting of ethanol and glycerol;
3. 0.05-10.0% by volume non-ionic surfactant and 0.001-5.0% by volume cationic surfactant;
4. ethylenediaminetetraacetic acid (EDTA); and
5. water

to said wound, wherein said composition kills or inhibits growth of bacteria within the wound infection in the absence of increased inflammation and edema at the site of the wound.

2. The method of claim 1 , wherein said wound infection comprises Staphylococcus aureus.

3. The method of claim 2 , wherein said Staphylococcus aureus are antibiotic resistant.

4. The method of claim 1 , wherein said wound infection comprises Pseudomonas aeruginosa.

5. The method of claim 1 , wherein said composition is co-administered with a bioactive agent.

6. The method of claim 1 , wherein said nanoemulsion comprises:
a) water;
b) polyoxyethylenesorbitan monolaurate;
c) glycerol or ethanol;
d) oil;
e) dimethyl benzyl ammonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).

7. The method of claim 1 , wherein said nanoemulsion comprises:
a) water;
b) a non-ionic surfactant selected from the group consisting of polyoxyethylenesorbitan monolaurate, polyoxyethylenesorbitan monooleate, and a poloxamer;
c) glycerol or ethanol;
d) oil;
e) a cationic surfactant selected from the group consisting of cetylpyridinium chloride (CPC), benzalkonium chloride, and alkyl dimethyl benzyl ammonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).

8. The method of claim 1 , wherein said nanoemulsion has a mean particle size of 0.2-0.8 microns.

9. The method of claim 1 , wherein said nanoemulsion has a mean particle size less than 0.5 microns.

10. The method of claim 1 , further comprising the step of co-administering an antimicrobial agent to said wound.

11. The method of claim 10 , wherein said antimicrobial agent is an antibiotic.

12. The method of claim 1 , wherein said nanoemulsion comprises:
a) water;
b) 0.05-10.0% polyoxyethylene sorbitan monolaurate;
c) 3-15% glycerol;
d) oil;
e) 0.001-5.0% benzalkonium chloride; and
f) ethylenediaminetetraacetic acid (EDTA).

Assignees

• Univ Michigan

Inventors

• Baker Jr James R
• Hemmila Mark R
• Wang Stewart C
• Hamouda Tarek
• Lipuma John J
• Knowlton Jessica Ann
• Makidon Paul E
• Blanco Luz
• Groom Ii Jeffery V
• Bielinska Anna U

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K31/198 Primary

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K31/341

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/14

  Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205) · CPC title